25,165 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Inlet Private Wealth LLC

Inlet Private Wealth LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,165 shares of the medical equipment provider’s stock, valued at approximately $2,658,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Northwestern Mutual Wealth Management Co. increased its holdings in Zimmer Biomet by 12.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,080 shares of the medical equipment provider’s stock valued at $877,000 after purchasing an additional 881 shares during the last quarter. Quarry LP acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $53,000. EP Wealth Advisors LLC boosted its stake in Zimmer Biomet by 10.5% during the 2nd quarter. EP Wealth Advisors LLC now owns 2,358 shares of the medical equipment provider’s stock worth $256,000 after acquiring an additional 225 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Zimmer Biomet during the second quarter valued at approximately $1,677,000. Finally, Massmutual Trust Co. FSB ADV increased its stake in Zimmer Biomet by 18.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 19,079 shares of the medical equipment provider’s stock valued at $2,060,000 after purchasing an additional 2,940 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Raymond James decreased their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Truist Financial boosted their target price on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Wells Fargo & Company boosted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Trading Down 1.1 %

NYSE ZBH opened at $109.36 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average of $107.94 and a 200-day moving average of $108.26. The company has a market cap of $21.77 billion, a PE ratio of 20.79, a PEG ratio of 1.90 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.65 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.